313 related articles for article (PubMed ID: 22570737)
1. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
[TBL] [Abstract][Full Text] [Related]
2. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.
Bode-Lesniewska B; Frigerio S; Exner U; Abdou MT; Moch H; Zimmermann DR
Genes Chromosomes Cancer; 2007 Nov; 46(11):961-71. PubMed ID: 17647282
[TBL] [Abstract][Full Text] [Related]
3. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
[TBL] [Abstract][Full Text] [Related]
4. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms.
Downs-Kelly E; Goldblum JR; Patel RM; Weiss SW; Folpe AL; Mertens F; Hartke M; Tubbs RR; Skacel M
Am J Surg Pathol; 2008 Jan; 32(1):8-13. PubMed ID: 18162764
[TBL] [Abstract][Full Text] [Related]
5. A cryptic EWSR1::DDIT3 fusion in myxoid liposarcoma: Potential pitfalls with FISH and cytogenetics.
Ibstedt S; de Mattos CBR; Köster J; Mertens F
Genes Chromosomes Cancer; 2023 Mar; 62(3):167-170. PubMed ID: 36379683
[TBL] [Abstract][Full Text] [Related]
6. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
[TBL] [Abstract][Full Text] [Related]
7. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
[TBL] [Abstract][Full Text] [Related]
8. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
Narendra S; Valente A; Tull J; Zhang S
Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
[TBL] [Abstract][Full Text] [Related]
9. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
Bento C; Andersson MK; Aman P
BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906
[TBL] [Abstract][Full Text] [Related]
10. Gene of the month: DDIT3.
Diaz-Perez JA; Kerr DA
J Clin Pathol; 2024 Mar; 77(4):211-216. PubMed ID: 38053287
[TBL] [Abstract][Full Text] [Related]
11. Myxoid liposarcoma with EWS-CHOP type 1 fusion gene.
Suzuki K; Matsui Y; Endo K; Kubo T; Hasegawa T; Kimura T; Ohtani O; Yasui N
Anticancer Res; 2010 Nov; 30(11):4679-83. PubMed ID: 21115923
[TBL] [Abstract][Full Text] [Related]
12. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
[No Abstract] [Full Text] [Related]
13. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.
Riggi N; Cironi L; Provero P; Suvà ML; Stehle JC; Baumer K; Guillou L; Stamenkovic I
Cancer Res; 2006 Jul; 66(14):7016-23. PubMed ID: 16849546
[TBL] [Abstract][Full Text] [Related]
14. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.
Pérez-Mancera PA; Bermejo-Rodríguez C; Sánchez-Martín M; Abollo-Jiménez F; Pintado B; Sánchez-García I
PLoS One; 2008 Jul; 3(7):e2569. PubMed ID: 18596980
[TBL] [Abstract][Full Text] [Related]
15. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.
de Vreeze RS; de Jong D; Tielen IH; Ruijter HJ; Nederlof PM; Haas RL; van Coevorden F
Mod Pathol; 2009 Feb; 22(2):223-31. PubMed ID: 18820664
[TBL] [Abstract][Full Text] [Related]
16. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
17. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
[TBL] [Abstract][Full Text] [Related]
18. The FUS-DDIT3 Interactome in Myxoid Liposarcoma.
Yu JSE; Colborne S; Hughes CS; Morin GB; Nielsen TO
Neoplasia; 2019 Aug; 21(8):740-751. PubMed ID: 31220736
[TBL] [Abstract][Full Text] [Related]
19. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
[TBL] [Abstract][Full Text] [Related]
20. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
Zinszner H; Albalat R; Ron D
Genes Dev; 1994 Nov; 8(21):2513-26. PubMed ID: 7958914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
